canakinumab
novartis
['mds', 'canakinumab']
great ppt by about the safety &amp; efficacy of il-1b antibody canakinumab in lr-mds. agree with him about exploring this agent in ccus. to that end our study of canakinumab in high risk ccus is now open.#ash22 
Clonal Hematopoesis,MDS,AML@OSU/The James Cancer Hospital.Acute Leukemia Clinical Research Director. Girl Mom, Vegetarian, Avid Reader, Traveller & Adventurer